Clinical trial
A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease…
NCT03367403 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT03367403 |
|---|---|
| Title | A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ) |
| Official title | Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Alzheimer Disease |
| Intervention type | Drug |
| Interventions | Donanemab, Placebo, LY3202626 |
| Enrollment | 272 |
| Start date | Dec 18, 2017 |
| Primary completion | Dec 4, 2020 |
| Completion | Sep 21, 2021 |
| First posted | Dec 8, 2017 |
| Last update posted | Oct 13, 2022 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: